ROS1 and lung carcinoma: The kinase domains of ALK and ROS1 share homology, and Crizotinib, an ALK-EML 4 inhibitor, was used to interfere with ROS1 fusion gene-positive and ALK-EML4 fusion gene-positive lung cancer cells, and Crizotinib was found to inhibit the growth of hcc78 cells (ROS1 fusion gene-positive) (Bergethon et al., 2012), Accordingly, some ALK-TKIs have been shown to be effective in patients with ros1 rearrangement (Huber et al., 2014).